Biohaven Ltd. Increase (Decrease) in Accounts Payable
Biohaven Ltd. (BHVN) reported Increase (Decrease) in Accounts Payable of $471.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-10
- Biohaven Ltd. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $1.69M, a 12.20% increase year-over-year.
- Biohaven Ltd. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$1.22M, a 1441.76% decline year-over-year.
- Biohaven Ltd. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$5.85M.
- Biohaven Ltd. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$2.14M, a 186.00% decline year-over-year.
- Biohaven Ltd. increase (decrease) in accounts payable for fiscal 2025 was -$6.39M, a 999.44% decline from fiscal 2024.
- Biohaven Ltd. increase (decrease) in accounts payable for fiscal 2024 was $710.00K, a 85.43% decline from fiscal 2023.
- Biohaven Ltd. increase (decrease) in accounts payable for fiscal 2023 was $4.87M, a 17.78% decline from fiscal 2022.
- Biohaven Ltd. increase (decrease) in accounts payable for fiscal 2022 was $5.93M, a 478.34% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $471.00K 10-Q · filed 2026-08-10 | -$5.38M derived: sum of 3 quarters · filed 2026-08-10 | -$7.51M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$1.22M 10-Q · filed 2026-05-04 | -$7.07M derived: sum of 2 quarters · filed 2026-05-04 | -$9.21M derived: sum of 3 quarters · filed 2026-05-04 | -$7.70M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$5.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$7.99M derived: sum of 2 quarters · filed 2026-03-02 | -$6.48M derived: sum of 3 quarters · filed 2026-08-10 | -$6.39M 10-K · filed 2026-03-02 |
| 2025-09-30 | -$2.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$629.00K derived: sum of 2 quarters · filed 2026-08-10 | -$538.00K 10-Q · filed 2025-11-10 | -$2.25M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $1.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $1.60M 10-Q · filed 2026-08-10 | -$116.00K derived: sum of 3 quarters · filed 2026-08-10 | $2.37M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $91.00K 10-Q · filed 2026-05-04 | -$1.62M derived: sum of 2 quarters · filed 2026-05-04 | $861.00K derived: sum of 3 quarters · filed 2026-05-04 | -$18.27M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | -$1.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $770.00K derived: sum of 2 quarters · filed 2026-03-02 | -$18.36M derived: sum of 3 quarters · filed 2026-03-02 | $710.00K 10-K · filed 2026-03-02 |
| 2024-09-30 | $2.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$16.64M derived: sum of 2 quarters · filed 2025-11-10 | $2.42M 10-Q · filed 2025-11-10 | $8.49M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | -$19.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$60.00K 10-Q · filed 2025-08-11 | $6.00M derived: sum of 3 quarters · filed 2026-03-02 | $3.48M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $19.07M 10-Q · filed 2025-05-12 | $25.13M derived: sum of 2 quarters · filed 2026-03-02 | $22.60M derived: sum of 3 quarters · filed 2026-03-02 | $20.19M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $6.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $3.54M derived: sum of 2 quarters · filed 2026-03-02 | $1.12M derived: sum of 3 quarters · filed 2026-03-02 | $4.87M 10-K · filed 2026-03-02 |
| 2023-09-30 | -$2.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$4.94M derived: sum of 2 quarters · filed 2024-11-12 | -$1.19M 10-Q · filed 2024-11-12 | $4.78M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | -$2.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $1.34M 10-Q · filed 2024-08-09 | $7.31M derived: sum of 3 quarters · filed 2025-03-03 | $5.66M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $3.75M 10-Q · filed 2024-05-09 | $9.72M derived: sum of 2 quarters · filed 2025-03-03 | $8.08M derived: sum of 3 quarters · filed 2025-03-03 | $7.75M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $5.97M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $4.33M derived: sum of 2 quarters · filed 2025-03-03 | $4.00M derived: sum of 3 quarters · filed 2025-03-03 | $5.93M 10-K · filed 2025-03-03 |
| 2022-09-30 | -$1.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$1.97M derived: sum of 2 quarters · filed 2023-11-14 | -$44.00K 10-Q · filed 2023-11-14 | -$2.52M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | -$325.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-31 | $1.60M 10-Q · filed 2023-07-31 | -$878.00K derived: sum of 3 quarters · filed 2024-02-29 | |
| 2022-03-31 | $1.93M 10-Q · filed 2023-05-12 | -$553.00K derived: sum of 2 quarters · filed 2024-02-29 | ||
| 2021-12-31 | -$2.48M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $1.02M 10-K · filed 2024-02-29 | ||
| 2021-09-30 | $3.50M 10-Q · filed 2022-11-09 | |||
| 2020-12-31 | $222.00K 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |